Aricept shows initial resilience to generic onslaught in Japan
This article was originally published in Scrip
Executive Summary
If initial trends are anything to go by, Eisai does not have too much to fear from the advent of generic competition in Japan to its top product, the Alzheimer's disease therapy Aricept (donepezil).